Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Pandemic Influenza Vaccine Market by Age Group (Adult, Paediatric): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03430

Pages: NA

Charts: NA

Tables: NA

Influenza vaccines treat influenza by developing antibodies in the body within two weeks after vaccination. These antibodies protect against infections with the help of the attenuated viruses in the vaccine. These vaccines contain killed or inactivated strains of the influenza virus. The drivers that drive the market growth are increase in the prevalence of influenza, increase in compliance with the influenza vaccine, and effective communication strategies between the prescriber and patients. However, the factors such as complexity of influenza vaccine development & approval system and stringent government regulations restraints the market growth. Moreover, technical developments prove as future opportunity for market growth.

The report segments the market on the basis of age group and region. Based on end users, the market is segmented into adult pandemic influenza vaccine and paediatric pandemic influenza vaccine. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players included in the report are AstraZeneca plc, GlaxoSmithKline plc, Novartis A.G, Sanofi S.A, Valneva SE, Lupin, Chiron Panacea Pvt Ltd., Solvay and Serum Institute of India Pvt. Ltd., Sementis AG.

Key Benefits

  • The study provides an in-depth analysis of the global pandemic influenza vaccine market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • Comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry is provided for the to assists stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps in understanding the trends in end users of pandemic influenza vaccines across the globe.
  • Key market players and their strategies have been provided to understand the competitive outlook of the industry.

 Key Market Segments

  • By Age Group
    • Adult
    • Paediatric
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Turkey
      • Argentina
      • Rest of LAMEA

 
Key Market Players

  • Lupin
  • Solvay
  • Valneva SE
  • Sanofi S.A
  • Serum Institute of India Pvt. Ltd.
  • AstraZeneca plc
  • Sementis AG.
  • Chiron Panacea Pvt Ltd.
  • Novartis A.G
  • GlaxoSmithKline plc

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PANDEMIC INFLUENZA VACCINE MARKET, BY AGE GROUP

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Age Group

    • 4.2. Adult

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Paediatric

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: PANDEMIC INFLUENZA VACCINE MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Age Group

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Pandemic Influenza Vaccine Market

        • 5.2.4.1. Market Size and Forecast, By Age Group

      • 5.2.5. Canada Pandemic Influenza Vaccine Market

        • 5.2.5.1. Market Size and Forecast, By Age Group

      • 5.2.6. Mexico Pandemic Influenza Vaccine Market

        • 5.2.6.1. Market Size and Forecast, By Age Group

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Age Group

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Pandemic Influenza Vaccine Market

        • 5.3.4.1. Market Size and Forecast, By Age Group

      • 5.3.5. Germany Pandemic Influenza Vaccine Market

        • 5.3.5.1. Market Size and Forecast, By Age Group

      • 5.3.6. Italy Pandemic Influenza Vaccine Market

        • 5.3.6.1. Market Size and Forecast, By Age Group

      • 5.3.7. Spain Pandemic Influenza Vaccine Market

        • 5.3.7.1. Market Size and Forecast, By Age Group

      • 5.3.8. UK Pandemic Influenza Vaccine Market

        • 5.3.8.1. Market Size and Forecast, By Age Group

      • 5.3.9. Russia Pandemic Influenza Vaccine Market

        • 5.3.9.1. Market Size and Forecast, By Age Group

      • 5.3.10. Rest Of Europe Pandemic Influenza Vaccine Market

        • 5.3.10.1. Market Size and Forecast, By Age Group

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Age Group

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Pandemic Influenza Vaccine Market

        • 5.4.4.1. Market Size and Forecast, By Age Group

      • 5.4.5. Japan Pandemic Influenza Vaccine Market

        • 5.4.5.1. Market Size and Forecast, By Age Group

      • 5.4.6. India Pandemic Influenza Vaccine Market

        • 5.4.6.1. Market Size and Forecast, By Age Group

      • 5.4.7. South Korea Pandemic Influenza Vaccine Market

        • 5.4.7.1. Market Size and Forecast, By Age Group

      • 5.4.8. Australia Pandemic Influenza Vaccine Market

        • 5.4.8.1. Market Size and Forecast, By Age Group

      • 5.4.9. Thailand Pandemic Influenza Vaccine Market

        • 5.4.9.1. Market Size and Forecast, By Age Group

      • 5.4.10. Malaysia Pandemic Influenza Vaccine Market

        • 5.4.10.1. Market Size and Forecast, By Age Group

      • 5.4.11. Indonesia Pandemic Influenza Vaccine Market

        • 5.4.11.1. Market Size and Forecast, By Age Group

      • 5.4.12. Rest of Asia Pacific Pandemic Influenza Vaccine Market

        • 5.4.12.1. Market Size and Forecast, By Age Group

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Age Group

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Pandemic Influenza Vaccine Market

        • 5.5.4.1. Market Size and Forecast, By Age Group

      • 5.5.5. South Africa Pandemic Influenza Vaccine Market

        • 5.5.5.1. Market Size and Forecast, By Age Group

      • 5.5.6. Saudi Arabia Pandemic Influenza Vaccine Market

        • 5.5.6.1. Market Size and Forecast, By Age Group

      • 5.5.7. UAE Pandemic Influenza Vaccine Market

        • 5.5.7.1. Market Size and Forecast, By Age Group

      • 5.5.8. Argentina Pandemic Influenza Vaccine Market

        • 5.5.8.1. Market Size and Forecast, By Age Group

      • 5.5.9. Rest of LAMEA Pandemic Influenza Vaccine Market

        • 5.5.9.1. Market Size and Forecast, By Age Group

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning, 2024

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. AstraZeneca Plc

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. GlaxoSmithKline Plc

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Novartis A.G

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Sanofi S.A

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Valneva SE

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. Lupin

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. Chiron Panacea Pvt Ltd.

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Solvay

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Serum Institute Of India Pvt. Ltd.

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. Sementis AG.

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PANDEMIC INFLUENZA VACCINE MARKET, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PANDEMIC INFLUENZA VACCINE MARKET FOR ADULT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PANDEMIC INFLUENZA VACCINE MARKET FOR PAEDIATRIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PANDEMIC INFLUENZA VACCINE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. NORTH AMERICA PANDEMIC INFLUENZA VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. NORTH AMERICA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 7. U.S. PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 8. CANADA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 9. MEXICO PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 10. EUROPE PANDEMIC INFLUENZA VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. EUROPE PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 12. FRANCE PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 13. GERMANY PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 14. ITALY PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 15. SPAIN PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 16. UK PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 17. RUSSIA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 18. REST OF EUROPE PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 19. ASIA-PACIFIC PANDEMIC INFLUENZA VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. ASIA-PACIFIC PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 21. CHINA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 22. JAPAN PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 23. INDIA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 24. SOUTH KOREA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 25. AUSTRALIA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 26. THAILAND PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 27. MALAYSIA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 28. INDONESIA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 29. REST OF ASIA PACIFIC PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 30. LAMEA PANDEMIC INFLUENZA VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 31. LAMEA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 32. BRAZIL PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 33. SOUTH AFRICA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 34. SAUDI ARABIA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 35. UAE PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 36. ARGENTINA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 37. REST OF LAMEA PANDEMIC INFLUENZA VACCINE, BY AGE GROUP, 2025-2033 ($MILLION)
  • TABLE 38. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 39. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 40. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 41. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 42. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 43. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 44. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 45. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 46. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 47. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 48. NOVARTIS A.G: KEY EXECUTIVES
  • TABLE 49. NOVARTIS A.G: COMPANY SNAPSHOT
  • TABLE 50. NOVARTIS A.G: OPERATING SEGMENTS
  • TABLE 51. NOVARTIS A.G: PRODUCT PORTFOLIO
  • TABLE 52. NOVARTIS A.G: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 53. SANOFI S.A: KEY EXECUTIVES
  • TABLE 54. SANOFI S.A: COMPANY SNAPSHOT
  • TABLE 55. SANOFI S.A: OPERATING SEGMENTS
  • TABLE 56. SANOFI S.A: PRODUCT PORTFOLIO
  • TABLE 57. SANOFI S.A: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 58. VALNEVA SE: KEY EXECUTIVES
  • TABLE 59. VALNEVA SE: COMPANY SNAPSHOT
  • TABLE 60. VALNEVA SE: OPERATING SEGMENTS
  • TABLE 61. VALNEVA SE: PRODUCT PORTFOLIO
  • TABLE 62. VALNEVA SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 63. LUPIN: KEY EXECUTIVES
  • TABLE 64. LUPIN: COMPANY SNAPSHOT
  • TABLE 65. LUPIN: OPERATING SEGMENTS
  • TABLE 66. LUPIN: PRODUCT PORTFOLIO
  • TABLE 67. LUPIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 68. CHIRON PANACEA PVT LTD.: KEY EXECUTIVES
  • TABLE 69. CHIRON PANACEA PVT LTD.: COMPANY SNAPSHOT
  • TABLE 70. CHIRON PANACEA PVT LTD.: OPERATING SEGMENTS
  • TABLE 71. CHIRON PANACEA PVT LTD.: PRODUCT PORTFOLIO
  • TABLE 72. CHIRON PANACEA PVT LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 73. SOLVAY: KEY EXECUTIVES
  • TABLE 74. SOLVAY: COMPANY SNAPSHOT
  • TABLE 75. SOLVAY: OPERATING SEGMENTS
  • TABLE 76. SOLVAY: PRODUCT PORTFOLIO
  • TABLE 77. SOLVAY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 79. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 80. SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS
  • TABLE 81. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 82. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. SEMENTIS AG.: KEY EXECUTIVES
  • TABLE 84. SEMENTIS AG.: COMPANY SNAPSHOT
  • TABLE 85. SEMENTIS AG.: OPERATING SEGMENTS
  • TABLE 86. SEMENTIS AG.: PRODUCT PORTFOLIO
  • TABLE 87. SEMENTIS AG.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PANDEMIC INFLUENZA VACCINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PANDEMIC INFLUENZA VACCINE MARKET
  • FIGURE 3. SEGMENTATION PANDEMIC INFLUENZA VACCINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PANDEMIC INFLUENZA VACCINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPANDEMIC INFLUENZA VACCINE MARKET
  • FIGURE 11. PANDEMIC INFLUENZA VACCINE MARKET SEGMENTATION, BY BY AGE GROUP
  • FIGURE 12. PANDEMIC INFLUENZA VACCINE MARKET FOR ADULT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PANDEMIC INFLUENZA VACCINE MARKET FOR PAEDIATRIC, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 18. COMPETITIVE DASHBOARD
  • FIGURE 19. COMPETITIVE HEATMAP: PANDEMIC INFLUENZA VACCINE MARKET
  • FIGURE 20. TOP PLAYER POSITIONING, 2024
  • FIGURE 21. ASTRAZENECA PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 22. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 23. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 24. GLAXOSMITHKLINE PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 25. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 26. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 27. NOVARTIS A.G: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. NOVARTIS A.G: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. NOVARTIS A.G: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. SANOFI S.A: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. SANOFI S.A: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. SANOFI S.A: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. VALNEVA SE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. VALNEVA SE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. VALNEVA SE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. LUPIN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. LUPIN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. LUPIN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. CHIRON PANACEA PVT LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. CHIRON PANACEA PVT LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. CHIRON PANACEA PVT LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. SOLVAY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. SOLVAY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. SOLVAY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. SERUM INSTITUTE OF INDIA PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. SEMENTIS AG.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. SEMENTIS AG.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. SEMENTIS AG.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Pandemic Influenza Vaccine Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved